Therapy should therefore not be discontinued in patients with established CVD who do not achieve the weight-loss targets observed in clinical trials
The hidden cost of informal tracking is fragmentation, where dose times, side effects, water intake, and food quality are scattered across notes and memory, making it hard for clinicians to adjust titration or for patients to spot early trends
While Wegovy, which contains the same active ingredient (Semaglutide) at a different dosage, is FDA-approved for chronic weight management, Aetna's coverage for it is a separate, and often equally complex, matter
I had struggled with my weight my entire life
It's more physiologic as opposed to having this drug that's in you all the time, that you don't really need in you all the time